HCV TREATMENT: ARE THERE STILL DIFFICULT TO TREAT PATIENTS?

Pol Stanislas

首页> 外文期刊>Liver international : >HCV TREATMENT: ARE THERE STILL DIFFICULT TO TREAT PATIENTS?

【24h】

HCV TREATMENT: ARE THERE STILL DIFFICULT TO TREAT PATIENTS?

机译：HCV治疗：仍然难以治疗患者吗？

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Liver international : 》 |2019年第12期| 共2页
作者
Pol Stanislas;
展开▼
作者单位

Univ Paris 05 Cochin Hosp APHP Hepatol Dept INSERM U1223 UMS 20 Paris France;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类内科学 ;
关键词

相似文献

外文文献
中文文献
专利

1. Value of Child-Turcotte-Pugh Score in Prediction of Treatment Response in “Difficult to Treat” Chronic HCV Cirrhotic Patients [J] . Taghrid Mohamed Abdalla, Sameh M. Abdel Monem, Hosam M. Dawod Open Journal of Gastroenterology . 2019 ,第11期

机译：儿童Turcotte-Pugh评分在“难治性”慢性HCV肝硬化患者治疗反应预测中的价值
2. Treatment with Glecaprevir/Pibrentasvir (G/P)-based regimens of patients with difficult to treat HCV infection. A compassionate use study. [J] . de Ledinghen Victor, Varaut Anne, Ursic-Bedoya Jose, Hepatology: Official Journal of the American Association for the Study of Liver Diseases . 2017 ,第Suppla1期

机译：用glecaprevir / pibrentasvir（g / p）治疗 - 基于难以治疗HCV感染的患者的方案。富有同情心的使用研究。
3. Sustained Virologic Response at 24 Weeks after the End of Treatment Is a Better Predictor for Treatment Outcome in Real-World HCV-Infected Patients Treated by HCV NS3/4A Protease Inhibitors with Peginterferon plus Ribavirin [J] . Tatsuo Kanda, Shingo Nakamoto, Reina Sasaki, International Journal of Medical Sciences . 2016 ,第4期

机译：在治疗结束后第24周持续的病毒学应答是用聚乙二醇干扰素加利巴韦林治疗的HCV NS3 / 4A蛋白酶抑制剂治疗的真实HCV感染患者中治疗结果的更好预测指标
4. Patients with HCV/HIV Co-infection Achieving a Sustained Virological Response Following HCV Treatment with Peginterferon alfa-2a (PEGASYS) plus Ribavirin (COPEGUS) have Improved Health Related Quality of Life [C] . D.T. Dieterich, M. Rodriguez Torres, J.K. Rockstroh International AIDS Conference . 2004

机译：HCV / HIV的患者在用Peginterferon Alfa-2a（Pegasys）加上利巴韦林（Copegegs）后HCV治疗后实现持续的病毒学反应，具有改善的健康相关的生活质量
5. Considerations Decision Makers Use to Decide Pharmacologic Treatment for Patients Infected with the Hepatitus C Virus (HCV) in State Prisons [D] . Castro, Juan. 2018

机译：决策者用于确定州监狱中感染丙型肝炎病毒（HCV）的患者的药物治疗注意事项
6. U.S. Multicenter Pilot Study of Daily Consensus Interferon (CIFN) Plus Ribavirin for Difficult-to-Treat HCV Genotype 1 Patients [O] . Samuel B. Ho, Bashar Aqel, Eric Dieperink, -1

机译：每日共识干扰素（CIFN）加利巴韦林在难治性 HCV基因型1患者中的美国多中心试验研究
7. MELD Score as a Predictor of Treatment Response of ‘Difficult to Treat’ Chronic HCV Patients [O] . Taghrid Mahmoud, Sameh Abdel Monem, Mahmoud Salim 2019

机译：作为“难以治疗”慢性HCV患者的治疗反应的预测因素。慢性HCV患者

HCV TREATMENT: ARE THERE STILL DIFFICULT TO TREAT PATIENTS?

著录项

相似文献

相关主题

期刊订阅